Daewoong Pharmaceutical has publicly disclosed the global Phase 2 clinical data for its idiopathic pulmonary fibrosis (IPF) treatment candidate, 'Bersiporocin' (DWN12088).
On September 6, during the '2026 European Respiratory Society (ERS 2026)' conference held in Barcelona, Spain, the company presented a poster detailing the baseline characteristics of 104 patients enrolled in the Phase 2 trial.
Idiopathic pulmonary fibrosis is a disease characterized by the hardening of lung tissue. It results from a complex interplay of inflammation and fibrosis signals, leading to excessive collagen production and accumulation, which gradually impairs lung function.
Bersiporocin is a novel drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits prolyl-tRNA synthetase (PRS), which is involved in collagen production, thereby reducing excessive collagen generation during the lung fibrosis process.
The analysis focused on the clinical and functional characteristics of all trial participants recruited from Korea and the U.S.
Among the 104 patients, 55 (52.9%) were Korean and 49 (47.1%) were American. Of these, 71 patients (68.3%) were receiving existing antifibrotic treatments, while 33 patients (31.7%) were not. The overall baseline characteristics of the patients were generally similar regardless of antifibrotic treatment status.
The average forced vital capacity (FVC) of the patients was approximately 77% of the predicted normal value, while the diffusion capacity of the lungs for carbon monoxide (DLCO) was about 51%. FVC is a key indicator of lung function, representing the amount of air a patient can forcefully exhale after taking a deep breath. DLCO measures how well gases, such as oxygen, are transferred from the lungs to the bloodstream.
Park Seong-su, CEO of Daewoong Pharmaceutical, stated, "We aim to secure the major results of the Phase 2 trial in the first half of next year and will accelerate development to provide a new treatment option for IPF patients worldwide."
Additionally, Daewoong Pharmaceutical recently received the Minister of Gender Equality and Family Award in the low birthrate overcoming category at the '13th National Contribution Awards 2026.' This recognition acknowledges the company's efforts to support employees' childbirth, childcare, and career development, fostering a work-life balance culture.
The National Contribution Awards honor companies and organizations that contribute to the sustainable development of the nation through management innovation, social contribution, and environmental, social, and governance (ESG) management.
On September 6, during the '2026 European Respiratory Society (ERS 2026)' conference held in Barcelona, Spain, the company presented a poster detailing the baseline characteristics of 104 patients enrolled in the Phase 2 trial.
Idiopathic pulmonary fibrosis is a disease characterized by the hardening of lung tissue. It results from a complex interplay of inflammation and fibrosis signals, leading to excessive collagen production and accumulation, which gradually impairs lung function.
Bersiporocin is a novel drug candidate developed by Daewoong Pharmaceutical. It selectively inhibits prolyl-tRNA synthetase (PRS), which is involved in collagen production, thereby reducing excessive collagen generation during the lung fibrosis process.
The analysis focused on the clinical and functional characteristics of all trial participants recruited from Korea and the U.S.
Among the 104 patients, 55 (52.9%) were Korean and 49 (47.1%) were American. Of these, 71 patients (68.3%) were receiving existing antifibrotic treatments, while 33 patients (31.7%) were not. The overall baseline characteristics of the patients were generally similar regardless of antifibrotic treatment status.
The average forced vital capacity (FVC) of the patients was approximately 77% of the predicted normal value, while the diffusion capacity of the lungs for carbon monoxide (DLCO) was about 51%. FVC is a key indicator of lung function, representing the amount of air a patient can forcefully exhale after taking a deep breath. DLCO measures how well gases, such as oxygen, are transferred from the lungs to the bloodstream.
Park Seong-su, CEO of Daewoong Pharmaceutical, stated, "We aim to secure the major results of the Phase 2 trial in the first half of next year and will accelerate development to provide a new treatment option for IPF patients worldwide."
Additionally, Daewoong Pharmaceutical recently received the Minister of Gender Equality and Family Award in the low birthrate overcoming category at the '13th National Contribution Awards 2026.' This recognition acknowledges the company's efforts to support employees' childbirth, childcare, and career development, fostering a work-life balance culture.
The National Contribution Awards honor companies and organizations that contribute to the sustainable development of the nation through management innovation, social contribution, and environmental, social, and governance (ESG) management.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.